TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that the Company received approval from the NASDAQ Stock Market for the transfer of the listing of its common stock from the NASDAQ Global Market to the NASDAQ Capital Market. The Company’s common stock will be transferred to the NASDAQ Capital Market effective as of the open of trading today. Listing on the NASDAQ Capital Market does not affect the Company’s ticker symbol, which will remain “ABPI”.
